Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Yuen discusses some new treatments in the pipeline and how personalized medicine could make an impact in HBV treatment.
While some think it is reasonable that the hepatitis C virus (HCV) could be eradicated in the next decade, it is not seen as a possibility for the hepatitis B virus (HBV).
With an estimated 257 million individuals suffering from HBV infections worldwide, treating the disease remains paramount.
The key to this is early screenings and detection, enabling doctors to start treatments as early as possible. There are several treatment options for patients, with new drugs currently being studied to further our ability to treat the virus.
In the latest episode of DocTalk, Man Fung Yuen, MD, PhD, discusses some of the new treatments in the pipeline including RG6346, an investigational treatment for chronic HBV. Yuen recently announced positive data from a phase 1 proof-of-concept trial showing the therapeutic candidate produced sustained HBsAg reductions, without yielding any serious adverse events.
Yuen, who is the Chief of the Division of Gastroenterology and Hepatology at the University of Hong Kong, said the drug, developed by Dicerna in collaboration with Roche, could make a major impact in treating this patient population.
Yuen also discussed how new advances in HBV treatment could usher in an era of personalized medicine for patients suffering from the viral infection.